Establishing new use criteria led to an 86% reduction in the utilization of sugammadex with no appreciable impact on measured outcomes.
Jerry Rebo, PharmD, BCPS, BCCCP, DPLA
Advertisement
Articles by Jerry Rebo, PharmD, BCPS, BCCCP, DPLA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
In the Fragmented Landscape of Long COVID Care, Pharmacists Are Essential
2
FDA Approves Gazyva for Active Lupus Nephritis
3
Amivantamab Shows 45% Response Rate in Pretreated Head and Neck Cancer: OrigAMI-4 Findings
4
KEYNOTE-755 Confirms Broad Efficacy of Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer
5
